Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James V. Caruso
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- 0.56
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.54
Financials
Net Income
$-6.93MEBITDA
$-6.93MFree Cash Flow
$-6.01MEPS (diluted)
$-0.57Shares Outstanding (diluted)
12.23M+22685.8%Operating Expenses
$7.20MCash & Debt
$33.99MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-21.79M | $-8.35 |
| 2024 | $0.00 | $-44.58M | $-36.52 |
| 2023 | $0.00 | $-42.77M | $-104.99 |
| 2022 | $0.00 | $-31.79M | $-135.18 |
| 2021 | $0.00 | $-24.12M | $-130.35 |
| 2020 | $0.00 | $-15.09M | $-228.55 |
| 2019 | $0.00 | $-14.09M | $-550.86 |
| 2018 | $0.00 | $-13.24M | $-1567.96 |
| 2017 | $0.00 | $-13.56M | $-3210.00 |
| 2016 | $0.00 | $-6.18M | $-6420.00 |
| 2015 | $0.00 | $-5.50M | $-21090.00 |
| 2014 | $0.00 | $-8.11M | $-53100.00 |
| 2013 | $0.00 | $-10.78M | $-114000.00 |
| 2012 | $0.00 | $-8.80M | $-138000.00 |
Valuation
CLRBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-51.72%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·7d ago·Positive
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.56 per share
Typical surprise +26.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.57 vs $-0.52miss
- Thu, May 14$-1.33 vs $-1.89beat
- Wed, Mar 4$-0.53 vs $-1.19beat
- Thu, Nov 13$-1.41 vs $-1.91beat
- Thu, Aug 14$-3.39 vs $-3.60beat
- Tue, May 13$-3.90 vs $-5.11beat
Estimates and results for CLRB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLRB officers and directors.
- Bought
- $619k
- Sold
- $8.6m
17 trades
7 trades
- Longcor Jarrodbought
- Longcor Jarrodbought
- Caruso James Vbought
- Caruso James Vbought
- Neis Johnsold
- Caruso James Vbought
- Caruso James Vbought
- Longcor Jarrodbought
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLRB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.